Xenetic Biosciences (XBIO) EBITDA (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly EBITDA came in at -$502117.0 in Q1 2026, up 46.72% YoY from -$342228.4 in Q1 2025, and up 19.41% on a QoQ basis from -$623027.0 in Q4 2025.
Xenetic Biosciences (XBIO) EBITDA (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of EBITDA data on file, last reported at -$502117.0 in Q1 2026.
- Quarterly EBITDA rose 46.72% year-over-year to -$502117.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (up 38.27% YoY) and the FY2025 annual result came in at -$2.8 million, up 32.58% from the prior year.
- EBITDA grew to -$502117.0 in Q1 2026, from -$623027.0 in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$499473.0 in Q3 2024 to a low of -$2.7 million in Q2 2022.
- A 5-year average of -$1.1 million and a median of -$1.1 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA slumped 138.29% — and 2024, when it jumped 56.44%.
- Tracing XBIO's EBITDA over 5 years: stood at -$1.6 million in 2022, then advanced by 19.68% to -$1.3 million in 2023, then rose by 12.47% to -$1.1 million in 2024, then surged by 43.32% to -$623027.0 in 2025, then rose by 19.41% to -$502117.0 in 2026.
- The last three EBITDA figures came in at -$502117.0 (Q1 2026), -$623027.0 (Q4 2025), and -$544734.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | -971,690.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -971,690.00 |
| Mar 31, 2026 | -502,117.00 |
| Dec 31, 2025 | -623,027.00 |
| Sep 30, 2025 | -544,734.00 |
| Jun 30, 2025 | -724,412.00 |
| Mar 31, 2025 | -942,409.00 |
| Dec 31, 2024 | -1.10 Mn |
| Sep 30, 2024 | -499,473.00 |
| Jun 30, 2024 | -1.34 Mn |
| Mar 31, 2024 | -1.27 Mn |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -1.15 Mn |
| Jun 30, 2023 | -1.20 Mn |
| Mar 31, 2023 | -915,175.00 |
| Dec 31, 2022 | -1.56 Mn |
| Sep 30, 2022 | -847,786.00 |
| Jun 30, 2022 | -2.69 Mn |
| Mar 31, 2022 | -1.62 Mn |
| Dec 31, 2021 | -1.87 Mn |
| Sep 30, 2021 | -1.38 Mn |